A positron-emission tomography study to determine brain exposure of [11C]savolitinib in healthy volunteers

Study identifier:D5084C00016

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase I, Open-label, Positron-Emission Tomography Study to Determine Brain Exposure of [11C]savolitinib in Healthy Volunteers

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

[11C]savolitinib, Savolitinib

Sex

All

Estimated Enrollment

8

Study type

Interventional

Age

45 Years - 65 Years

Date

Study Start Date: 22 Apr 2024
Estimated Primary Completion Date: 28 Jun 2024
Estimated Study Completion Date: 28 Jun 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Mar 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria